Quest Diagnostics Stock News

SECAUCUS, N.J. , Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024...

New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health® , a Quest Diagnostics (NYSE: DGX) company that provides evidence-based patient enga...

Other companies whose consensus 2025 revenue estimates have increased the most include BlackRock and Coterra Energy.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusive agreement with Quest Diagnostics, a leading provider of diagnostic information services, under which Quest will validate and offer a lab-developed test based on the Augurex 14-3-3η (eta) biomark...

SECAUCUS, N.J. , Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025.

Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLabs acquisition, aims to expand its footprint and diversify operations, despite short-term EPS dilution. The company faces risks from PAMA reimbursement cuts and labor market challenges but expects l...

Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusti...

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.